Vertex Phase 1 study compares VX-581 tablet and suspension formulations in healthy adults

This week's update covers one Vertex Pharmaceuticals trial record for VX-581.

• This Phase 1, open-label, randomized, crossover study evaluates the relative bioavailability of a tablet formulation of VX-581 compared to a suspension formulation, including its safety and tolerability, in healthy adult subjects.¹ The study targets cystic fibrosis as the underlying indication, but eligibility is limited to healthy volunteers aged 18 to 55 years.¹ The trial is listed as active, not recruiting, with an actual enrollment of 16 participants.¹ Primary completion is estimated for October 27, 2026.